A Study Assessing the Addition of Stereotactic Body Radiation Therapy to Standard Drug Therapy in People with Breast Cancer


Full Title

Stereotactic Body Radiation Therapy (SBRT) to Ablate Isolated disease on systemic therapy to improve progression free survival in Metastatic Breast cancer (AIM-B)


In this study, researchers want to see if adding stereotactic body radiation therapy (SBRT) to standard drug therapy is effective for people with estrogen receptor (ER)-positive HER2-positive oligometastatic breast cancer that has gotten worse at one metastatic site despite medical treatment. Oligometastatic breast cancer is cancer that has spread to a small number of parts of the body. SBRT delivers extremely precise, very intense doses of radiation to cancer cells.

The investigators believe that using SBRT to treat the metastatic site where the cancer has worsened may prevent the cancer from getting worse in other metastatic sites or spreading. Participants will continue to take their usual drug therapy while they receive SBRT.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have oligometastatic breast cancer that is positive for ER and HER2 and has been responding well to drug therapy for at least 6 months, but shows evidence of one metastatic site getting worse.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Amy Xu at 646-888-6863.




Phase II (phase 2)




ClinicalTrials.gov ID